Less common KIT mutations, as well as mutations in the ASXL1, RUNX1, TET2, SRSF2, JAK2 or N/KRAS genes are also implicated in SM pathogenesis and significantly affect patient prognosis [15]. This evidence concerns the gene SRSF2 and systemic mastocytosis.